Tofacitinib Use in Adults with Chronic Inflammatory Disease During the Severe Acute Respiratory Syndrome Coronavirus 2 Pandemic: What Is Known So Far?

BACKGROUND: Concerns have been raised that the risk of severe acute respiratory syndrome coronavirus 2 infection, or more severe or critical coronavirus disease 2019 (COVID-19), may be higher in immunocompromised individuals receiving immunomodulatory therapies compared with immunocompetent individu...

Descripción completa

Detalles Bibliográficos
Autores principales: Howland, Samantha, Deuring, J. Jasper, Zhou, Xiaofeng, Chen, Yan, Mota, Licia MH, Ungaro, Ryan C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8310567/
https://www.ncbi.nlm.nih.gov/pubmed/34334801
http://dx.doi.org/10.1016/j.curtheres.2021.100639

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8310567/
https://www.ncbi.nlm.nih.gov/pubmed/34334801
http://dx.doi.org/10.1016/j.curtheres.2021.100639

Ejemplares similares